US EditionPublished • loading... • Updated
Biocon Biologics reaches settlement with Amgen for Denosumab biosimilars commercialisation
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Biocon Biologics reaches settlement with Amgen for Denosumab biosimilars commercialisation
Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon, announced a settlement agreement with Amgen Inc. enabling commercialisation of its Denosumab biosimilars in Europe and other global markets. The agreement permits Biocon Biologics to commercialise both Denosumab biosimilars, Vevzuo and Evfraxy, in Europe starting 2 December 2025. Other terms of the settlement remain confidential. Shreehas Tambe, CEO and Man…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
